Skip to main content

Testing the Impact of Personalized Medicine

The goal of personalized medicine is to implement advances in biomarker pharmacology, molecular diagnostics and genomics to improve the health of patients afflicted by a wide range of medical conditions. Dramatic advances in genomics have identified numerous disease/therapeutic associations now placing this goal within sight. Yet such advances often bypass underserved populations, resulting in significant inequalities of care.

IU School of Medicine’s Institute for Personalized Medicine in collaboration with Eskenazi Health is conducting a study to evaluate the economic and clinical outcomes associated with embedding a pharmacogenomics program in a system that serves as a health care safety net in Indianapolis.

Eskenazi Health

Eskenazi Health handles more than 1.2 million outpatient visits a year through the hospital and network of 10 community health centers. With more than 990,000 outpatient visits and 15,000 adult admissions annually, the payor mix includes 45 percent uninsured, 26 percent Medicaid and 18 percent Medicare patients. This health care system has more than 40 years of experience in digital medical record implementation and a proven track record of innovation in medical informatics that is based in the Regenstrief Institute. 

Clinical Research

The INGENIOUS trial is designed to test the hypothesis that a CLIA certified genotyping targeted at 24 widely used drugs is associated with significant reductions in hospital and outpatient economic costs incurred over one year. The study will also test whether pharmacogenetic testing is associated with significant improvements in clinical outcomes over one year.

This study is enrolling a total of 6,000 patients, with 2,000 patients assigned to a pharmacogenetic testing arm and 4,000 to a control arm who will be followed but not tested. The study is prospective since practice patterns change, and retrospective designs cannot be used to assess the impact of a prospective change. It is randomized between an intervention arm and one that receives no intervention in order that a genotyped group can be compared with one in which undisturbed, routine clinical care is carried out in patients taking the same drugs. Both arms will be followed for a year.

Subjects will be enrolled starting at six months into the funding period, and the study will continue accepting participants for two years, so the last person enrolled will be at 2.5 years, and follow up will be completed at 3.5 years, allowing six months for analysis at the end of the study. A pharmacogenetic test, involving 51 SNPs in 16 genes will be carried out at the beginning of the study in patients in the testing arm upon prompting by an index medication: one of 24 selected as being supported by validated guidelines.

Principal Investigators

5010-Skaar, Todd

Todd C. Skaar, PhD

Professor of Medicine

Read Bio

4838-Dexter, Paul

Paul R. Dexter, MD

Associate Professor of Clinical Medicine

Read Bio

Co-Investigators

Samir K. Gupta, MD

Professor of Medicine

David M. Haas, MD

Robert A. Munsick Professor of Obstetrics & Gynecology

Raj Vuppalanchi, MD

Professor of Medicine

Gail H. Vance, MD

Sutphin Professor of Cancer Genetics

Rolf P. Kreutz, MD

Associate Professor of Clinical Medicine

John T. Callaghan, MD, PhD

Associate Dean for VA Research

Marc B. Rosenman, MD

Adjunct Associate Professor of Pediatrics

Todd C. Skaar, PhD

Professor of Medicine

Zeruesenay Desta, PhD

Professor of Medicine

Lang Li, MD, PhD

Adjunct Professor of Medical & Molecular Genetics

Victoria Pratt, PhD

Professor of Clinical Medical & Molecular Genetics

Michael T. Eadon, MD

Assistant Professor of Medicine